Managing Editor
Following a successful Rx-to-OTC switch last year, Alcon is wasting no time expanding its Pataday line of prescription-strength OTC products. The latest addition to the line is Pataday Once Daily Relief Extra Strength, which joins the original-strength Pataday Once Daily Relief and Pataday Twice Daily Relief.
Pataday Once Daily Relief Extra Strength offers 24 hours of eye allergy itch relief with a single dose that the company said begins working in minutes. It helps combat eye itching caused by animal hair, dander, grass, pollen and ragweed for people aged 2 years old and older.
“The introduction of Pataday Once Daily Relief Extra Strength brings a full 24 hours of eye allergy itch relief over the counter for millions of Americans with eye allergies,” said Sergio Duplan, president of Alcon North America. “We’re thrilled to provide access to the strongest concentration of olopatadine, previously the No. 1 doctor-prescribed eye allergy itch rel
Alcon Inc. Investors: Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S.
1
The drop, formerly prescribed as Pazeo, joins Alcon s over-the-counter ocular allergy portfolio to meet a variety of patient needs
The expansion of the Pataday portfolio of products will strengthen Alcon s leadership position in the U.S. eye allergy OTC market
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Pataday
Once Daily Relief Extra Strength (
olopatadine hydrochloride ophthalmic solution 0.7%) is now available in-store and online at U.S. retailers, following its 2020 approval by the Food and Drug Administration (FDA) for sale over-the-counter (OTC). As Alcon s third Rx-to-OTC switch in the past twelve months, Pataday Once Daily Relief Extra Strength joins the #1 selling OTC eye allergy relief brand and is poised to help the company maintain its leadership position in the ocular all
Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S. apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Alcon Inc. Swiss: Alcon Announces Launch of AcrySof IQ Vivity, the First and Only Non-Diffractive Extended Depth of Focus Intraocular Lens in the U.S.
Vivity X-WAVE technology delivers extended range of vision while maintaining a monofocal-like visual disturbance profile 1,2
PC-IOL option for cataract patients who may not be a candidate for a diffractive IOL
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, has commercially launched the first and only non-diffractive extended depth of focus intraocular lens (IOL) in the U.S. the AcrySof IQ Vivity
TM IOL (Vivity). This new presbyopia-mitigating lens is now available to all U.S. ophthalmologists for patients undergoing cataract surgery. Cataracts are the most common cause of vision loss globally.
Alcon Inc. Investors: Alcon Announces Launch of AcrySof IQ Vivity, the First and Only Non-Diffractive Extended Depth of Focus Intraocular Lens in the U.S.
Vivity X-WAVE technology delivers extended range of vision while maintaining a monofocal-like visual disturbance profile 1,2
PC-IOL option for cataract patients who may not be a candidate for a diffractive IOL
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, has commercially launched the first and only non-diffractive extended depth of focus intraocular lens (IOL) in the U.S. the AcrySof IQ Vivity
TM IOL (Vivity). This new presbyopia-mitigating lens is now available to all U.S. ophthalmologists for patients undergoing cataract surgery. Cataracts are the most common cause of vision loss globally.